CytoSorbents Corporation CTSO 深 滬
已收盤 02-06 16:00:00 美东时间
0.672
+0.042
+6.62%
華盛通- 最 高0.70
- 今 開0.66
- 成交量 5.27万股
- 最 低 0.66
- 昨 收 0.6303
- 總市值 4220.45万
- 52周最高 1.39
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 0.60
- 委 比 95.65%
- 總股本 6280.43万
- 歷史最高 15.24
- 量 比 0.54
- 振 幅 6.35%
- 歷史最低 0.09
- 每 手 1
- 風險率 0.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Watching Cytosorbents; Zacks Small-Cap Research Gives Stock $5 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01132026_CTSO_Kerr.pdf
01-14 02:12
CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75%
Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75%DrugSorb®-ATR De Novo
01-12 20:25
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.
2025-12-17 02:03
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
HC Wainwright & Co. Maintains Neutral on CytoSorbents, Lowers Price Target to $0.75
HC Wainwright & Co. analyst Sean Lee maintains CytoSorbents (NASDAQ:CTSO) with a Neutral and lowers the price target from $1 to $0.75.
2025-11-14 21:07
CytoSorbents Q3 Adj. EPS $(0.04) Beats $(0.05) Estimate, Sales $9.485M Miss $10.034M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 14.89 percent. This is a 50 percent increase over losses of $(0.08) per share from the
2025-11-14 05:09
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
2025-09-17 10:15
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.
2025-09-16 21:11
